Patient description: A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications. Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA), as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  CVD Clinical 1. Subject is ≥18 years old 2. Eligible for percutaneous endovascular intervention 3. Documented severe (70%) symptomatic intracranial stenosis 4. Acceptable candidate for intracranial stenting 5. Subject (or legal guardian) understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed 6. Subject willing to comply with all specified follow-up evaluations Angiographic 1. Target lesion located in intracranial internal artery, intracranial vertebral artery, basilar artery or middle cerebral artery 2. Target lesion must be symptomatic 3. Target lesion diameter stenosis ≥70% 4. Reference vessel diameter (RVD): ≥2.0 mm to ≤6.0 mm 5. Cumulative target lesion length (area to be treated must be completely coverable by one study stent) ≤30 mm 6. Target lesion is presumed accessible by endovascular treatment. 7. One non target lesion may be treated in a non target vessel 8. Non-target lesion in non-target vessel must be treated with a commercially available stent. 9. Treatment of a non target lesion (if performed) must be deemed a clinical angiographic success, without requiring use of unplanned additional stent(s). 10. Treatment must be completed prior to treatment of target lesion  Contraindication to ASA, or to both clopidogrel and ticlopidine Known hypersensitivity to atorvastatin Known allergy to stainless steel Known allergy to platinum Previous treatment of the target vessel with angioplasty Previous treatment of the target vessel with stent Previous treatment of any non target vessel with stent within 9 months of the index procedure Planned endovascular treatment to post index procedure Planned or actual target vessel treatment with an unapproved device, directional or rotational intracranial atherectomy, laser, cutting balloon or transluminal extraction catheter immediately prior to stent placement Cerebral infarction within 1 month prior to the index procedure